Pharmaceuticals
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China
Affamed to obtain sole commercialization rights upon regulatory approval in Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Target to address unmet medical needs for millions of Chinese migraine patients. SHANGHAI, Jan. 17, ...
2023-01-17 08:00
6067
JUNIPER BIOLOGICS PARTNERS WITH CARIS LIFE SCIENCES® FOR MOLECULAR PROFILING DISTRIBUTION IN SOUTH EAST ASIA
SINGAPORE, Jan. 12, 2023 /PRNewswire/ -- Singapore-headquartered Juniper
Biologics Pte Ltd
2023-01-12 13:02
3332
DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
- Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel 3-month ext...
2023-01-12 06:00
3341
CGTN: TCM continues to play significant role in treating COVID-19
BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19. As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...
2023-01-11 23:09
4830
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform. "This first...
2023-01-11 09:00
3459
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel
sirolimus-eluting balloon, has received conditional FDA Investigational Device
Exemption (IDE) approval to initiate its pivotal clinical trial for the
treatment of coronaryde novo lesions.
2023-01-11 09:00
4212
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-11 00:00
4510
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...
2023-01-10 21:05
3446
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...
2023-01-10 21:05
3931
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...
2023-01-10 21:00
4128
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...
2023-01-10 21:00
3703
CSafe Bolsters Its Digital Ecosystem Launching TracSafe Data Loggers and CSafe Connect Portal
TracSafe fit-for-purpose data loggers link directly to the comprehensive CSafe Connect customer portal creating the next iteration of a progressive customer-focused digital ecosystem MONROE, Ohio, Jan. 10, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive ...
2023-01-10 20:00
5113
Sarah Otten Joins Medison Pharma as VP, GM Americas Region
Sarah Otten will lead Medison's Americas region covering Canada and Latin
America. Sarah brings vast geographical expansion experience in international
markets.
PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ --
Medison Pharma
2023-01-10 19:54
2795
Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report
Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON, Jan. 10, 2023 /PRNewswire/ ...
2023-01-10 16:00
2649
Bangkok Dusit Medical Services extends partnership with CNN to explore global health issues
HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest healthcare network inThailand, reinforces
its long-standing partnership with CNN International Commercial (CNNIC) with
the sponsorship of 'Vital Signs
2023-01-10 11:24
3236
Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target
NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a
clinical stage artificial intelligence (AI)-driven drug R&D company, today
announces positive topline results of safety, tolerability, and
pharmacokinetics (PK) from thePhase I clinical trial of INS018_055
2023-01-10 05:00
7195
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-10 00:00
4708
Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong
HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) inHong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medic...
2023-01-09 18:57
5672
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
SYDNEY, Jan. 6, 2023 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today announced the extension of the backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights Offer...
2023-01-06 15:05
5149
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
ROCKVILLE, Md. and SUZHOU, China, Jan. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-01-06 12:22
5127
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
8846
Sungrow Calls for Scenario-based and integrated systems to Accelerate the Next Phase of the Renewable Energy Transition
2026-09-09 22:26
7427
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
2026-09-07 13:00
6845